PLX - AMEX

Good morning, ladies and gentlemen. And welcome to the Protalix Biotherapeutics Third Quarter 2023 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to our host, Mr. Chuck Padala of LifeSci Advisors, Investor Relations for Protalix. You may begin the conference.

Thank you, operator and welcome to the Protalix Biotherapeutics Third Quarter 2023 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO of Protalix; and Eyal Rubin, Senior Vice President and Chief Financial Officer. A press release announcing the results and the update was issued this morning and is now available on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release in this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in the Protalix's filing with the U.S. Securities and Exchange Commission. I will now turn the call over to Mr. Dror Bashan. Dror?

Thank you, Chuck. And welcome everyone to our third quarter 2023 financial results and business update call. Before we begin, I would like to take a moment to acknowledge the situation here in Israel. We at Protalix are horrified by the devastating events that have been taking place in recent weeks. It is an extremely challenging time and we are heartbroken for the victims, families, friends and loved ones, many of us being personally impacted. Our hearts and prayers go out to all these those affected and we remain dedicated to the safety and wellbeing of our team. We are committed to provide our families, friends and colleagues any and all support they need at this time. At the same time, we want to reassure you that we are continuing to operate as usual. There have been no disruptions to our facilities and we do not currently anticipate any interruption to the supply of our products Elfabrio and Elelyso. We appreciate all those who have been reached out to Protalix to express their concern and support and we thank you for joining us today. I will now review our recent progress and accomplishments. Following my remarks, Eyal will provide a more detailed review of our financial results and then of course, we will open the line for questions. Let me now turn to our accomplishments this quarter. Since receiving FDA and EMA approval for Elfabrio, our commercial partner, Chiesi has focused on commercial launch in both the United States and the European Union. We are also pleased that Elfabrio has been granted additional regulatory approvals outside the EU, like in Great Britain and Switzerland, and we look forward to continued global growth of Elfabrio. Having now secured the approval of two drug products, Elfabrio and Elelyso, we are now focusing our attention to develop our pipeline assets with the potential to address high unmet needs for patients with limited therapeutic options. Our most advanced development candidate is PRX-115 for the potential treatment of severe gout. We are currently sponsoring a Phase 1 first in human clinical trial of PRX-115 to evaluate its safety, pharmacokinetics, pharmacodynamics and immunogenicity. It is a double-blind, placebo-controlled single ascending dose trial of up to 56 participants. 42 participants have been dosed today in this first in human trial. We expect to announce topline results from this study in mid-2024. We believe PRX-115 is potentially a good candidate to target this market. Our next pipeline candidate is PRX-119 for the potential treatment of NETs-related diseases. NETs are web like structures released by activated neutrophils that trap and kill a variety of microorganisms. Excessive formation or ineffective clearance of NETs can result in different pathological effects and has been observed in various autoimmune inflammatory and fibrotic conditions. We look forward to providing with updates on these programs as they progress. There are currently several other preclinical programs and we will update regarding these programs once applicable. On the corporate side, we welcome Dr. Eliot Forster, as Chairman of our Board of Directors, succeeding Mr.

Thank you, Dror. And thank you everyone for joining today's call. Let me review our third quarter 2023 financials. We recorded revenues from selling goods of $10.2 million during the three months ended September 30th, 2023, an increase of $1.4 million or 16% compared to revenues of $8.8 million for the three months ended September 30th, 2022. The increase resulted primarily from an increase of $3 million in sales to Chiesi, following the approval by the FDA and the EMA, as Dror mentioned, of Elfabrio, and of $0.6 million in sales to Brazil, partially offset by $2.2 million decrease in sales to Pfizer. Recorded revenues from license and R&D services of $0.2 million for the three months ended September 30th, 2023, a decrease of $5.2 million, or 96%, compared to revenues of $5.4 million for the three months ended September 30, 2022. Revenues from license and R&D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. As of March 1st, 2023, sponsorship of the extension studies was transferred to Chiesi, and Chiesi is now administering all open label extension studies. Cost of goods sold was $4.9 million for the three months ended September 30th, 2023, a decrease of $2.2 million, or 31%, from cost of goods sold of $7.1 million for the three months ended September 30th, 2022. The decrease in cost of goods sold was primarily the result of the decrease in sales to Pfizer, partially offset by an increase in sales of Elfabrio to Chiesi and of Elelyso to Brazil. For the three months ended September 30th, 2023, our total research and development expenses were approximately $3.7 million comprised of approximately $1 million of subcontractor-related expenses, approximately $1.9 million of salary and related expenses, approximately $0.2 million of materials-related expenses and approximately $0.6 million of other expenses. For the three months ended September 30th, 2022, our total research and development expenses were approximately $7.4 million comprised of approximately $4.9 million in subcontractor-related expenses, approximately $1.7 million of salary and related expenses, approximately $0.2 million of materials-related expenses and approximately $0.6 million of other expenses. Total decrease in research and developments expenses was $3.7 million, or 50%, compared to the three months ended September 30th, 2022. The decrease in research and development expenses primarily resulted from the completion of our Fabry clinical program and the regulatory processes related to the BLA and MAA review of Elfabrio by the applicable regulatory agencies. Selling, general and administrative expenses were $3.7 million for the three months ended September 30, 2023, an increase of $0.9 million, or 32%, compared to $2.8 million for the three months ended September 30th, 2022. The increase resulted primarily from an increase of approximately $0.6 million in salary and related expenses due to one-time cash bonuses and an increase in share-based compensation. Financial income, net was $0.2 million for the three months ended September 30, 2023, compared to financial expenses, net of $0.4 million for the three months ended September 30, 2022. The change resulted primarily from an increase of $0.3 million in interest income. In the three months ended September 30, 2023, we recorded income taxes of approximately $0.1 million which were primarily the result of the provision for current taxes in respect of Section 174 of the U.S. Tax Cuts and Jobs Act, which was enacted in December 2017. Cash, cash equivalents and short term bank deposits were approximately $41 million at September 30th, 2023. Net loss for the three months ended September 30th, 2023 was approximately $1.9 million, or $0.03 per share, basic, and $0.04 per share diluted, compared to a net loss of $3.6 million, or $0.07 per share, basic and diluted, for the same period in 2022. I will now turn the call back to you, Dror.

Thank you, Eyal. In concluding this earnings call, I would like to know that we at Protalix are proud of our accomplishments. We have a proven platform technology with two approved therapeutics driving a rich and sustainable pipeline of assets. A worldclass team, a strong balance sheet supporting our strategic plans and a strategic vision to creating a long-term value for our stockholders. We look forward to updating you in the future in our progress. Before we start taking questions, I would like to note that we are praying for our friends and family during this challenging time. One that is filled with pain. I'm grateful for our entire Protalix team, their enduring commitment and resolve at this time as we develop a portfolio for patients with unmet medical needs is noteworthy. Now I would like to ask the operator to open the call for questions, please.

[Operator Instructions] The first question comes from the line of Boobalan Pachaiyappan with H.C. Wainwright

Hi, this Boobalan Sorry for the voice. I'm still recovering from sore throat. So thanks for taking our questions. Firstly, with respect to revenue from selling goods. I see that the revenue dropped from $15 million in second quarter to $10 million in the third quarter. Can you discuss the underlying factors for this drop in revenue and also what are your expectations for revenue in the fourth quarter?

Thank you, Boobalan for the question. So in terms of the decrease, part of the decrease is decrease in sales to Pfizer and part of it is decrease in sales to Chiesi, mentioned in the previous call, the sales to Chiesi are basically their inventory buildup. At this point, the sales to Chiesi are not indicative of the penetration of sales in the market. So obviously, as they build the inventory, there's going to be fluctuation in the next year and a half or even two years during the term that they're building the inventory and so it materially also penetrating the market and building their presence in the markets. With respect to your second question, about guidance on the revenue for the fourth quarter, we usually don't provide guidance for revenue, especially since the POs from Chiesi and from Brazilian Pfizer are dynamic, especially at this point, where Chiesi is the majority of the sales and they are building up their presence in the market. So I guess that it's going to take time until we'll be able to share forecasts and feel comfortable giving those forwarding statements.

Okay, fair enough. And then, congrats on winning FDA, sorry, the regulatory approval in UK and Switzerland. So I was wondering if you could provide or maybe at a high level discuss the Fabry disease market opportunity in the UK and Switzerland, and also which countries can we expect to approve Elfabrio in the upcoming quarters?

So actually the drug was approved already in most of the, if I may say, western countries in Europe. So the United Kingdom is not part of the EU, but it's certainly an important market. Also in Switzerland it was approved, and the idea is indeed to move on to other markets outside the EU, including Japan where Chiesi initiated the study in order to register the drug later on and other markets as well. As for the specific size of the Fabry market in the UK, I don't have it in front of me. And also this is Chiesi, if I may say, a role right now. So once we will have more data or Chiesi will release more data, we will be able to share it with you. But it's certainly the UK is a very important market in the Europe. Let's put this way.

Okay, thanks for the color. Let's switch gears and discuss your clinical programs, especially PRX-115, the ongoing Phase 1 study. So I'd like to get some additional color on some of the items that you're listed in the exclusion criteria. So I was looking at the clinicaltrials.gov website. And so some of the criteria, especially the exclusion criteria, so it says you're excluding patients with one or more Gaucher in the last one year and those with subcutaneous tophi or those with advanced renal diseases, they're also excluded. So I'm trying to understand is the strategy to target mild or moderate forms of gout without the renal complication, if I may? So you can clarify more on that.

Yes, sure. Thank you for that. So actually it's a Phase 1 study. It's a single dose. So it's the first time we actually infuse it to participants. The participants are actually volunteers with hyperuricemia. They are not and the idea is first to check safety, of course. And then to see if indeed we reduce the hyperuricemia to normal levels or acceptable levels and then take it further. So we measure multiple aspects in order to be able to move on, of course, subject to safety to multiple to like a multiple ascending dose later on in 2024. So it does not indicate right now. The idea is not to indicate for mild patients at all. Actually, it's for severe gout patients.

Okay. Thank you for the color. One last question, if I may. So again, with respect to PRX-115. So I know you're collecting immunogenicity data and blood uric acid levels as well. So I'm curious, what do you expect to see in these two data, especially Phase 1 study? What are your expectations?

So again, we would like to see safety for sure. And then we will analyze from a PKPD point of view additional measurements to see if we have indications for reduction, of course, of the hyperuricemia and other parameters in order, again, to see frequency of dosing and other signals. that will enable us, if I may say, to take further steps or more calculated steps for the next study.

Okay, thank you for taking all my questions.

Yes, and again, just to make sure, the intent at least is to enroll up to 56 subjects. So I think it's enough of a number to, or we hope it's enough of a number to get enough information to move on. I won't say minimize the risk, but with less risk, of course. Safety for sure, but more than that.

Next question comes from the line of John Vandermosten with

All right, thank you, Dror and Eyal. Good day to you. Beyond cost how much of your expense structure is oriented towards the Elfabrio business?

Okay. Can you repeat the question? I can hardly hear you. I'm sorry.

Oh, I'm sorry. Beyond cost, how much of your expense structure is oriented towards the Elfabrio business now?

In terms of cost structure, other than manufacturing, which takes something like three to four months a year, and the production of three to four months a year is sufficient to supply and provide half of the patient population worldwide, we're not investing at present in Elfabrio.

Okay. And how do you see your capital structure changing now that you have two revenue generating products, and then also keeping in mind that there's the convertible bet on the balance sheet.

That's a good question. A, we truly we have two revenue generating products out there. Since we are not doing anything in the equity capital markets, so obviously, I guess gradually, slowly, but surely when revenues are going to start to ramp up, the big boys are going to join the party and we're going to see that we have a stable streamline of revenues and we are accumulating cash. So it's a different company. It's not a biotech, a typical biotech company in the development stage. At present, we don't see this change. As we said, the company at this point is self-sustained. We don't see any need to raise money in the foreseeable future for the ongoing operations. So I guess that's going to take time. Over time, I guess that the capital structure is going to change.

Okay. And I think that are coming due next year in about a year. And then quarterly cash burn, can you give us some help on how to forecast that going forward? I noticed it was a little bit greater than net income for the quarter and I just wanted to see if you could help us understand how that might flow through for the next several quarters.

Yes, so I think that I responded to this one previously too by Boobalan. And since we are just in a phase of revenue ramp up and Chiesi just starting to penetrate the market and building the presence, slowly but surely, I guess that that's going to fluctuate. So we don't feel comfortable at this point sharing the forecasts for the next couple quarters. Yes, I think it's very, very, very fluctuating. They can decide that they are pulling two batches, one batch, for even technical reason delaying one. So I think at this point it's going to be irresponsible to share forecasts for the short term. Long term, as I said in the next day, you're going to have to, that's going to be mostly an inventory buildup with a runway that will ramp up, I'm talking about sales obviously, we'll ramp over time.

Okay, and then shifting to PRX-115 and assuming that topline comes out as expected or better in the middle of next year, what are the next steps there? Would that be P phase 2 or I guess I'm just wondering what we should expect to see from that development program.

So we intend to do a multiple dose following the single dose that we do now and then once we have, which is actually a Phase 2 and then we will continue from there.

Okay, and just one last one on 119. What are the next steps for that program?

So we, thank you for that. So we will gather information in the near future, if I may say, from the different preclinical studies and other data that we have. And we'll go for, if I may say, kind of a portfolio go-no-go meeting. And if indeed we decide to go ahead, we will share and continue to toxicology in Phase 1.

Thank you. This concludes today's question and answer session. I would now like to turn the floor over to Dror Bashan for closing comments.

So thank you everybody for your participation. And I appreciate the time. And we look forward speaking with you on our next call for 2023 results. And I hope with a more peaceful time for us here in Israel. Thank you all.